Cero Therapeutics Holdings, Inc. last reported quarterly results on Oct 11, 2024, for Q3 FY2024 (the quarter ended Sep 30, 2024): diluted EPS of -$170.22. It usually reports 11 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 11 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 11, 2024
11 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-4
-213.3%
|
-170.22
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CERO (OTC), CEROW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870404
- Former names
- CERO THERAPEUTICS HOLDINGS, INC. (until Oct 7, 2026); PHOENIX BIOTECH ACQUISITION CORP. (until Feb 14, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.